Medos Medizintechnik AG was merged into Xenios AG. This streamlines processes within the company and at the same time it grows closer to the parent company Fresenius Medical Care AG & Co. KGaA.
Medos Medizintechnik AG (Medos) was founded in 1987 with a focus on cardiopulmonary solutions. Together with Novalung GmbH (Novalung), the company was united under the umbrella of Xenios in 2013. Since then, Xenios offers solutions for extracorporeal cardiac as well as pulmonary support. Novalung was already fully integrated into Xenios in 2019. With the integration of Medos, what was originally three companies has now become one.
Since the end of 2016, Xenios has been part of Fresenius Medical Care, the leading provider of products and services for people with kidney diseases. Medos’ merger will enable leaner processes within Xenios, while at the same time pushing the integration of Xenios products and treatments into the parent company.
Even though Medos will disappear as a company, cardiopulmonary products will remain in the Xenios portfolio. These act as an important pillar in the area of multi-organ support within the parent company Fresenius Medical Care.
